TTX-030
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Identifiers | |
| CAS Number | |
TTX-030 is an experimental anti-CD39 monoclonal antibody developed by AbbVie to treat pancreatic cancer.[1][2][3][4]
References[edit]
- ^ "Pipeline". AbbVie. Retrieved 25 November 2023.
- ^ Lerner, Alana G.; Kovalenko, Maria; Welch, Megan; Cruz, Tracy dela; Jones, Jeff; Wong, Clifford; Spatola, Bradley; Eberhardt, Meghan; Wong, Andrew; Fung, Wanchi; Lagpacan, Leanna; Losenkova, Karolina; Yegutkin, Gennady; Soros, Vanessa; Corbin, John; Beers, Courtney; Moesta, Achim K. (1 July 2019). "Abstract 5012: Targeting CD39 with a first-in-class inhibitory antibody prevents ATP processing and increases T-cell activation". Cancer Research. 79 (13_Supplement): 5012. doi:10.1158/1538-7445.AM2019-5012. S2CID 213484199.
- ^ Spatola, Bradley N.; Lerner, Alana G.; Wong, Clifford; dela Cruz, Tracy; Welch, Megan; Fung, Wanchi; Kovalenko, Maria; Losenkova, Karolina; Yegutkin, Gennady G.; Beers, Courtney; Corbin, John; Soros, Vanessa B. (1 January 2020). "Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism". mAbs. 12 (1). doi:10.1080/19420862.2020.1838036. PMC 7646477. PMID 33146056.
- ^ Wainberg, Zev; Kang, Yoon-Koo; Lee, Keun-Wook; Kim, Seung Tae; Chao, Joseph; Catenacci, Daniel; Oh, Sung Yong; Soares, Heloisa P.; Selfridge, J. Eva; Cha, Yongjun; Skeel, Roland T.; Kim, Hyung-Don; Tran, Anh; Moesta, Achim; Dela Cruz, Tracy; Singhal, Anil; Jahn, Thomas M.; Dayyani, Farshid (15 June 2022). "Abstract CT015: Safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with chemoimmunotherapy for the first line treatment of locally advanced or metastatic gastric/GEJ cancer". Cancer Research. 82 (12_Supplement): CT015. doi:10.1158/1538-7445.AM2022-CT015. S2CID 249726929.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |